RevenanasBook a free audit

M&A

Argenx acquires Unnatural Products for up to $1.15B to expand oral peptide capabilities

Biotech

M&A

Key Facts

Signal Type

M&A

Industry

Biotech

Companies

argenx, Unnatural Products, Merck & Co., Novartis, Forte Biosciences

Date

What Happened

Argenx (Amsterdam, NL) has agreed to acquire Unnatural Products (UNP) for up to $1.15 billion, including $550 million upfront plus development and regulatory milestones. The deal brings UNP's macrocyclic peptide discovery platform and its 50+ person team in Santa Cruz, California, in-house as argenx's peptide hub. UNP had previously partnered with Merck & Co. (2024), argenx (2025), and Novartis (2026).

Who Is Affected

Argenx's Santa Cruz site becomes its macrocyclic peptide discovery hub, retaining UNP's team and platform. The acquisition expands argenx's capabilities beyond its traditional antibody focus, best known for Vyvgart (anti-FcRn antibody fragment). Argenx continues active business development after its $2.2 billion Forte Biosciences deal in July 2026, which added an anti-CD122 antibody (FB102) for vitiligo and celiac disease.

Market Impact

The deal follows industry trends in oral peptide delivery, as demonstrated by Johnson & Johnson's Icotyde and Merck's Lipfendra, and Gilead's $1.28 billion acquisition of PepStar Therapeutics' oral IL-23 inhibitor. Argenx's acquisition signals continued investment in oral peptide modalities and platform-based M&A.

  • Integration services for the Santa Cruz hub and platform
  • Lab informatics and data management for peptide discovery workflows
  • Peptide synthesis and manufacturing support for scaled operations

What to Watch

Post-close integration of UNP's platform and team into argenx's operations, including potential vendor engagements for lab informatics, peptide synthesis, and facility build-out. Argenx's continued BD activity following the Forte Biosciences deal suggests ongoing integration needs across multiple acquisitions.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner